Australia Pharmacovigilance Market Size & Outlook
Australia pharmacovigilance market, 2018-2030 (US$M)
Related Markets
Australia pharmacovigilance market highlights
- The Australia pharmacovigilance market generated a revenue of USD 148.3 million in 2023 and is expected to reach USD 258.8 million by 2030.
- The Australia market is expected to grow at a CAGR of 8.3% from 2024 to 2030.
- In terms of segment, phase 4 was the largest revenue generating product life cycle in 2023.
- Phase 3 is the most lucrative product life cycle segment registering the fastest growth during the forecast period.
Pharmacovigilance market data book summary
| Market revenue in 2023 | USD 148.3 million |
| Market revenue in 2030 | USD 258.8 million |
| Growth rate | 8.3% (CAGR from 2023 to 2030) |
| Largest segment | Phase 4 |
| Fastest growing segment | Phase 3 |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pre Clinical, Phase 1, Phase 2, Phase 3, Phase 4 |
| Key market players worldwide | Accenture PLC Class A, IQVIA Holdings Inc, Cognizant Technology Solutions Corp Class A, Linical Americas, International Business Machines Corp, Labcorp Holdings Inc, ArisGlobal, Capgemini SE, ITClinical, Icon PLC, TAKE Solutions, PAREXEL, Wipro Ltd ADR, United Biosource Corporation, FMD K&L, BioClinica |
Other key industry trends
- In terms of revenue, Australia accounted for 2.0% of the global pharmacovigilance market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China pharmacovigilance market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 340.5 million by 2030.
Phase 4 was the largest segment with a revenue share of 75.99% in 2023. Horizon Databook has segmented the Australia pharmacovigilance market based on pre clinical, phase 1, phase 2, phase 3, phase 4 covering the revenue growth of each sub-segment from 2018 to 2030.
The market growth in the country is anticipated to grow owing to the increasing incidence of chronic diseases and the growing geriatric population. As a result, this has increased the demand for clinical trials and ADR monitoring in Australia.
According to a study published by NCBI, hospitalization caused due to ADR increases by approximately 6% every year, coupled with ADR in-hospital deaths accounting for 2.4%. The significant increase in ADR has motivated market players to develop technologically advanced services and tools for safety monitoring, resulting in market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pharmacovigilance Market Scope
Pharmacovigilance Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia pharmacovigilance market size, by product life cycle, 2018-2030 (US$M)
Australia Pharmacovigilance Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
